Wednesday March 20, 2019 10:42

Heathcare Press Release : 02 Dec 2015

ESCEO: Why Patented Crystalline Glucosamine Sulfate (pCGS) is Different From Other Glucosamines in Heathcare—02 Dec 15

A task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and international KOLs has reached a consensus about implementing the ESCEO algorithm in practice and about developing a consensus paper on

Ryzodeg(R) Delivers Significantly Lower Rates of Hypoglycaemia and Nocturnal Hypoglycaemia in a Heathcare—02 Dec 15

New analyses demonstrate that Ryzodeg(R) (insulin degludec/insulin aspart) achieved successful glycaemic control with significantly lower rates of hypoglycaemia (low blood sugar) and nocturnal hypoglycaemia in patients with type 2 diabetes versus BIAsp

New Data Show Lilly#s Once-Weekly Trulicity(R) (dulaglutide) Solution for Injection is Effective as Heathcare—02 Dec 15

New data from a completed Phase 3 trial show Trulicity(R) (dulaglutide) solution for injection 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering HbA1c from baseline after 24 weeks of treatment.1 Trulicity

New data highlight impact of post-meal hyperglycaemia on people with Heathcare—02 Dec 15

New data from four analyses[1],[2],[3],[4] demonstrate that post-meal hyperglycaemia (when blood sugar goes too high after eating) is associated with a negative physical and emotional impact on people with type 1 and type 2 diabetes[3], greater use of

New data reveal why physicians and people with type 2 diabetes uncontrolled on basal insulin are Heathcare—02 Dec 15

Results from the Perceptions of Control (POC) study showed that people with type 2 diabetes uncontrolled on basal insulin were reluctant to intensify insulin therapy due to concerns such as medication side effects, perceptions of getting sicker and not

Victoza(R) (liraglutide) provides greater glycaemic control than SGLT-2 Heathcare—02 Dec 15

New findings from a network meta-analysis show that treatment with Victoza(R) (liraglutide) provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to sodium-glucose co-transporter 2 (SGLT-2) inhibitors in